2015-01-30T10:39:25-06:00 2014-06-30 KPMG LLP 345 PARK AVENUE NEW YORK NY 10154 990 2013-07-01 231907729 JDRF INTERNATIONAL % JDRF INTERNATIONAL JDRF 2124797551 26 BROADWAY 15TH FLOOR Suite NEW YORK NY 10004 MARK GREENE CFO 2124797551 2015-01-30 true D DUNCAN P01249521 2124797551 2013 2016-04-25 22:37:26Z DEREK RAPP 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 264395948 false X www.jdrf.org X 1970 PA JDRF'S MISSION IS TO FIND A CURE FOR TYPE I DIABETES AND ITS I DIABETES THROUGH THE SUPPORT OF RESEARCH. SEE SCHEDULE O 34 29 946 300000 14283 6810 196010663 210068935 0 0 9200541 8724630 1012287 1086957 206223491 219880522 106005315 98317342 0 0 68158134 75662068 339000 339000 26572210 34993292 41387310 209495741 215705720 -3272250 4174802 196040120 207538339 162509815 163676967 33530305 43861372 X JDRF'S MISSION IS TO FIND A CURE FOR TYPE I DIABETES AND ITS COMPLICATIONS THROUGH THE SUPPORT OF RESEARCH. SEE SCHEDULE O false false 98317342 98317342 DIRECT RESEARCH FUNDING - FOR THE FY14 PERIOD ENDING JUNE 30, 2014, JDRF DIRECTLY FUNDED $98.3 MILLION IN RESEARCH GRANTS AND AGREEMENTS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O 21415048 RESEARCH SUPPORT - TO HELP DEFINE AND DIRECT ITS RESEARCH PROGRAMS AND TO FOSTER COLLABORATION WITH OTHERS INVOLVED WITH T1D RESEARCH, JDRF ORGANIZES SCIENTIFIC MEETINGS, SYMPOSIA, WORKSHOPS, AND CONFERENCES. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O 51463000 PUBLIC EDUCATION - JDRF EDUCATES THE PUBLIC ABOUT T1D AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION, SEE SCHEDULE O 171195390 true true false true false false false false false true true true false false true true true false false true true true false true true true false true false true false false false false false false true true true false false false true true false false false true X 332 3 true 946 true true true true IS NL DA false false false true true false false false true false X 34 29 false false false false false false false true true false true true true true true true true true true true true true AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X JDRF INTERNATIONAL 2124797551 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 X DIANE ADAMS FY13-15 CHAIRMAN OF THE BOARD 20.0 X X 0 0 0 SHANNON ALLEN FY13-15 BOARD MEMBER 4.0 X 0 0 0 DAVID REHR FY13-15 BOARD MEMBER 4.0 X 0 0 0 ELLEN LEAKE FY12-14 BOARD MEMBER 3.0 X 0 0 0 KAREN CASE FY11-14 BOARD MEMBER 3.0 X 0 0 0 TOM CHAPMAN FY11-14 BOARD MEMBER 3.0 X 0 0 0 MATTHEW COHN FY11-14 BOARD MEMBER 3.0 X 0 0 0 DEREK RAPP FY11-14 BOARD MEMBER 3.0 X 0 0 0 JULIA GREENSTEIN CHAIR, DEVELOPMENT 7.0 X 264742 0 18326 REBECCA DAVIES FY11-14 TREASURER/ CHAIR, FINANCE 7.0 X X 0 0 0 MAARTEN DE GROOT FY12-14 SECRETARY/ CHAIR, NOMINATING 7.0 X X 0 0 0 RED MAXWELL FY12-14 BOARD MEMBER 3.0 X 0 0 0 CAROL OXENREITER FY11-14 CHAIR, RESEARCH 7.0 X 0 0 0 NICOLE JOHNSON FY13-15 CHAIR, INTERNATIONAL AFFAIRS 5.0 X 12000 0 0 MIKE LEE FY13-15 BOARD MEMBER 3.0 X 0 0 0 PREETISH NIJHAWAN FY13-15 CHAIR, MARKETING & COMM. 4.0 X 0 0 0 BILL PARSONS FY13-15 BOARD MEMBER 3.0 X 0 0 0 PAM SAGAN FY13-14 CHAIR, ADVOCACY 7.0 X 0 0 0 LARRY SOLER FY13-15 BOARD MEMBER 3.0 X 0 0 0 PAM EDMONDS FY13-15 BOARD MEMBER 3.0 X 0 0 0 NICK BRIEN FY14 BOARD MEMBER 4.0 X 0 0 0 NANETTE DETURK FY14-16 CHAIR, COMPENSATION 7.0 X 0 0 0 MICHELLE GRIFFIN FY14-16 BOARD MEMBER 3.0 X 0 0 0 JOHN BRADY FY14-16 CHAIR, T1D VOICES COUNCIL 5.0 X 0 0 0 STEPHEN NEWMAN MD FY14-16 CHAIR, CHANCELLORS 4.0 X 0 0 0 TIMOTHY ST CLAIR FY14-16 CHAIR, AUDIT 5.0 X 0 0 0 DAVID WHEADON CHAIR, INVESTMENTS 5.0 X 410525 0 9262 MARGO LUCERO BOARD MEMBER 3.0 X 243470 0 23422 CYNTHIA RICE BOARD MEMBER 3.0 X 239632 0 35223 NANETTE DETURK FY14-16 BOARD MEMBER 3.0 X MICHELLE GRIFFIN FY14-16 BOARD MEMBER 3.0 X JOHN BRADY FY14-16 BOARD MEMBER 4.0 X STEPHEN NEWMAN MD FY14-16 BOARD MEMBER 3.0 X TIMOTHY ST CLAIR FY14-16 BOARD MEMBER 3.0 X EDWARD J SEBALD CFO & ASST. TRES 50.0 X 232834 0 37363 JEFFREY BREWER PRESIDENT AND CEO 50.0 X 262500 0 23140 DAVID W NELMS FY12-14 CHIEF HR OFFICER & ASST. SECY 50.0 X 0 0 0 LORRAINE STIEHL FY12-14 VP & CHIEF OPERATIONS OFFICER 50.0 X 0 0 0 DAVID WHEADON EVP, RESEARCH & ADVOCACY 50.0 X 410525 9262 DR RICHARD A INSEL EVP RESEARCH 50.0 X 536450 0 38736 MARK FISCHER-COLBRIE FY13-15 ASST. VP / RESEARCH 50.0 X 0 0 0 AARON KOWALSKI VP, RESEARCH 50.0 X 244696 35740 MARGO LUCERO VP, CORPORATE DEVELOPMENT 50.0 X 243470 23422 CYNTHIA RICE SVP, GOV'T RELATIONS/ ADVOCACY 50.0 X 239632 35223 3340476 0 289119 153 false true false LW ROBBINS 201 SUMMER STREET HOLLISTON MA 01746 FUNDRAISING CONSULT 2248418 CONVIO INC 2000 DANIEL ISLAND DRIVE CHARLESTON SC 29492 FUNDRAISING SYSTEMS 2432683 HICKORY PRINTING SOLUTIONSLLC PO Box 69 HICKORY NC 28603 PRINTING CONSULTANT 712062 GSW WORLDWIDE 1180 AVE OF THE AMERICAS NEW YORK NY 10036 AD CONSULTANT 1224642 DDC ADVOCACY 1250 EYE STREET NW WASHINGTON DC 20005 PUBLIC AFFAIRS 656000 91 4650283 128028787 77389865 14685688 210068935 0 1660898 14283 1646615 0 0 0 0 0 26519613 19455881 7063732 7063732 7063732 24994300 128028787 24994300 0 1015535 65245 950290 950290 0 MISCELLANEOUS REVENUE 900099 136667 136667 136667 219880522 14283 9797304 68690807 68690807 0 29626535 29626535 0 1422402 873355 226162 322885 128024 78607 20356 29061 58496924 35917111 9301011 13278802 1647628 1020854 252241 374533 9641660 5919979 1533024 2188657 4325430 2655814 687743 981873 4509209 3702254 316242 490713 490678 369971 37292 83415 244830 184602 18607 41621 556494 419596 42294 94604 339000 339000 808948 609947 61480 137521 31405 23679 2387 5339 4722110 2653826 406101 1662183 587306 352384 108064 126858 4219551 2531731 776397 911423 0 10233680 6140208 1882997 2210475 3494086 2348026 401820 744240 0 2940642 1976111 338174 626357 0 0 4431000 2658600 815304 957096 488717 293230 89924 105563 OUTREACH EXPENSES 1509638 893706 258148 357784 DUES & FEES 1615857 956587 276312 382958 OTHER MISC EXPENSES 503159 297870 86040 119249 215705720 171195390 17938120 26572210 X 3083042 1109971 185059 1788012 2520529 1871397 11478825 14556180 20964333 31697456 13762501 12611584 0 0 0 0 0 0 0 0 3444264 3507142 27790287 8977747 19880384 18812540 67706583 59891458 53814254 61437447 2468447 2650935 0 0 0 502200 196040120 207538339 13856286 17125273 139614273 137384458 6579425 6755269 0 0 0 0 0 0 0 0 0 0 2459831 2411967 162509815 163676967 X -850019 1740091 27580079 35034733 6800245 7086548 33530305 43861372 196040120 207538339 4174802 6156265 X false true X true false X 192947945 198202755 195105087 196010663 210068935 992335385 0 0 192947945 198202755 195105087 196010663 210068935 992335385 691748 991643637 3001134 3183733 2070575 2055756 1660898 11972096 0 0 35418 29449 6810 71677 172582 295028 117723 74636 136667 796636 1005175794 0.98654 0.98439 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false 1000000 1000000 2000000 3000000 300158 162802 462960 250000 250000 500000 750000 92270 17263 109533 true true false true 1570 true 2035 true 6000 true 487864 true 88378 false 585847 false JDRF LOBBYING ACTIVITIES FORM 990- SCH-C- GENERAL STATEMENT OF ACTIVITIES JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with T1D, the goal of JDRF is to create a world without T1D. Through research and advocacy, JDRF is accelerating progress on the most promising opportunities to cure, treat, and prevent T1D. JDRF's advocacy includes lobbying activity to ensure Congress continues to invest in critically important medical research and puts in place policies to advance the discovery, development, and delivery of better therapies for T1D. JDRF staff and volunteers communicate with government officials through email, phone calls, and meetings, to educate them on issues and encourage the advancement of legislation. 6908880 1136000 109000 7935880 6898880 100000 81000 171000 6908880 5806880 1227000 350000 485000 6898880 5413880 526000 133000 5806880 5207251 1098629 892000 5413880 0.06400 0.89300 0.04300 false false 4643287 1032639 3610648 23147000 7945108 15201892 18812540 FOREIGN HEDGE FUNDS NON-PUBLIC 15909219 F US-NON-PUBLIC INVESTMENT FUNDS 45528228 F 61437447 0 SPLIT INTEREST CHRT RMDR TRUST 2411967 2411967 X 225227839 6156265 6156265 219071574 808948 808948 219880522 214896772 214896772 808948 808948 215705720 ORGANIZATION'S ENDOWMENT FUNDS FORM 990, PART X, LINE 28 & 29 THE INTENDED USE OF THE ORGANIZATION'S ENDOWMENT FUNDS IS TO USE THE FUNDS FOR BOTH SPECIFIC PROJECTS AS WELL AS SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. INCOME TAX POSITION OF JDRF INT. 990 SCH-D, PART X, LINE 2 JDRF is a not for profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is organized under the laws of the Commonwealth of Pennsylvania. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Income generated from activities unrelated to JDRF's exempt purpose is subject to tax under Internal Revenue Code Section 511. Unrelated Business Income Tax liability was insignificant for the years ending June 30, 2014 and 2013. true North America Grantmaking RESEARCH GRANTS 4307254 East Asia and the Pacific Grantmaking RESEARCH GRANTS 3765634 Europe (Including Iceland and Greenland) Grantmaking RESEARCH GRANTS 20087771 Middle East and North Africa Grantmaking RESEARCH GRANTS 1465876 Central America and the Caribbean Investments 15909219 Europe (Including Iceland and Greenland) 1 1 Program Services RESEARCH ADMIN 245600 1 1 1 1 45781354 45781354 East Asia and the Pacific 654108 CHECK/WIRE N/A N/A North America 109869 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 255000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 480450 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 297500 CHECK/WIRE N/A N/A Middle East and North Africa 347680 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 117310 CHECK/WIRE N/A N/A East Asia and the Pacific 410283 CHECK/WIRE N/A N/A East Asia and the Pacific 489828 CHECK/WIRE N/A N/A East Asia and the Pacific 90000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 250000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 202592 CHECK/WIRE N/A N/A East Asia and the Pacific 424612 CHECK/WIRE N/A N/A North America 349762 CHECK/WIRE N/A N/A North America 961703 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1877317 CHECK/WIRE N/A N/A East Asia and the Pacific 288080 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 800000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 433383 CHECK/WIRE N/A N/A East Asia and the Pacific 109320 CHECK/WIRE N/A N/A North America 271877 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1009957 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1291799 CHECK/WIRE N/A N/A East Asia and the Pacific 342639 CHECK/WIRE N/A N/A North America 53440 CHECK/WIRE N/A N/A North America 296846 CHECK/WIRE N/A N/A North America 111716 CHECK/WIRE N/A N/A North America 165000 CHECK/WIRE N/A N/A North America 157559 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 475705 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 334835 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 46884 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1279635 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 249201 CHECK/WIRE N/A N/A East Asia and the Pacific 413319 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 149943 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 338289 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 150000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 393550 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 294399 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 133343 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 582593 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1499291 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 830682 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 315000 CHECK/WIRE N/A N/A North America 552982 CHECK/WIRE N/A N/A East Asia and the Pacific 7355 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 280001 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 447112 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 75000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 610000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 1509387 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 30000 CHECK/WIRE N/A N/A Middle East and North Africa 1000000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 534000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 220000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 995461 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 207609 CHECK/WIRE N/A N/A North America 1300000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 51592 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 101393 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 350000 CHECK/WIRE N/A N/A East Asia and the Pacific 5187 CHECK/WIRE N/A N/A East Asia and the Pacific 8584 CHECK/WIRE N/A N/A East Asia and the Pacific 10000 CHECK/WIRE N/A N/A Middle East and North Africa 85000 CHECK/WIRE N/A N/A East Asia and the Pacific 30000 CHECK/WIRE N/A N/A East Asia and the Pacific 163540 CHECK/WIRE N/A N/A East Asia and the Pacific 476211 CHECK/WIRE N/A N/A Middle East and North Africa 80000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 275000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 12000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 165000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 219840 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 30000 CHECK/WIRE N/A N/A Europe (Including Iceland and Greenland) 100664 CHECK/WIRE N/A N/A 61 15 true false true true false false GRANT MONITORING PROCEDURES SCH-F PART I LINE 2 Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X X X X true LW ROBBINS 201 SUMMER STREET HOLLISTON MA 01746 MAIL PROCESSOR false 6160582 339000 5821582 CAR PROGRAM LLC 3755 OMEC CIRCLE 4 RANCHO CORDOVA CA 95742 CAR DONATION true 309522 146037 163485 6470104 485037 5985067 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY SEATTLE GALA 5035271 687176 4348095 217255 336539 133383 ILL GALA 3878726 680940 3197786 40058 242419 282913 115550 416 144109090 126660671 17448419 1259654 2667865 2760756 3845404 13092504 153023087 128028787 24994300 1259654 2925178 3003175 4464856 13341437 24994300 1015535 40000 25245 1015535 40000 25245 65245 950290 AL AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY true false false false 1.00000 GARY CURTO 26 BROADWAY-14TH FLOOR NEW YORK NY 10004 false GARY CURTO TAX MANAGER -JDRF 0 FILING GAMING APPLICATIONS AND REPORTS X true 950290 SCHEDULE G, PART I, LINE 2 THE CAR PROGRAM LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. THE CAR PROGRAM LLC RAISED $309,522 WITH TOTAL EXPENSES OF $146,037. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY THE CAR PROGRAM ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-14 WAS $163,485. THE CAR PROGRAM IS LOCATED AT 3755 OMEC CIRCLE, RANCHO CORDOVA, CA 95742 SCHEDULE G, PART I, LINE 2 LW ROBBINS ACTS AS A PFR/FRC FOR THE FUNCTION THEY PERFORM FOR JDRF. THEY ARE A MAILING PROCESSOR WITH VARIOUS FUNCTIONS AS A FUNDRAISING CONSULTANT. THE AMOUNT PAID TO LW ROBBINS WAS $339,000 FOR FUNDRAISING CONSULTATION; THE BALANCE WAS FOR PRODUCTS AND SERVICES. THIS IS THE THIRD YEAR OF A THREE YEAR CONTRACT. LW ROBBINS IS LOCATED AT 201 SUMMER STREET, HOLLISTON, MA 01746 true BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 9TH AVE SEATTLE WA 98101 910653422 501(C)3 1928880 N/A N/A BLACK HILLS REGIONAL EYE INSTITUTE 2800 3RD ST RAPID CITY SD 57701 060646973 501(C)3 29048 N/A N/A BRIGHAM AND WOMENS HOSPITAL INC 77 AVE- LOUIS PASTEUR BOSTON MA 02115 042312909 501(C)3 482932 N/A N/A CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE CLEVELAND OH 44106 341018992 501(C)3 250000 N/A N/A CHILDRENS HOSPITAL BOSTON 300 LONGWOOD AVE BOSTON MA 02115 042774441 501(C)3 3013540 N/A N/A BROWN UNIVERSITY PO BOX 1920 PROVIDENCE RI 02912 050258809 501(C)3 406859 N/A N/A CHILDRENS HOSPITAL OF PHILADELPHIA 1930 BROAD STREET PHILADELPHIA PA 19104 135598093 501(C)3 53320 N/A N/A EAST BAY RETINA CONSULTANTS INC 3300 WEBSTER ST OAKLAND CA 94609 943209895 19886 N/A N/A EASTERN VIRGINIA MEDICAL SCHOOL 358 MOWBRAY ACH NORFOLK VA 23501 237053028 501(C)3 110000 N/A N/A HENRY FORD HEALTH SYSTEM 7800 W OUTER DR DETROIT MI 48202 580566256 501(C)3 150000 N/A N/A ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 237025620 501(C)3 250000 N/A N/A AUSTIN RETINA ASSOCIATES 801 WEST 38TH STREET AUSTIN TX 78705 742034080 176787 N/A N/A HARVARD MEDICAL SCHOOL 200 LONGWOOD AVE BOSTON MA 02115 042103580 501(C)3 1989699 N/A N/A CORNELL UNIVERSITY 144 EAST AVE ITHACA NY 14850 150532082 501(C)3 200000 N/A N/A INDIANA UNIVERSITY 620 UNION DR INDIANAPOLIS IN 46202 356018940 501(C)3 624475 N/A N/A BETH ISRAEL MEDICAL CENTER 1 BROOKLINE AVE BOSTON MA 92121 135564934 501(C)3 46864 N/A N/A JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE 600 N EOLFE ST BALTIMORE MD 21224 520595110 501(C)3 37970 N/A N/A JOSLIN DIABETES CENTER 1 JOSLIN PL BOSTON MA 02215 042203836 501(C)3 3642738 N/A N/A LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 4660 LA JOLLA SAN DIEGO CA 92037 330328688 501(C)3 5196 N/A N/A FOUNDATION FOR THE NATIONAL INST OF HEALTH 9650 ROCKVILLE PIKE BETHESDA MD 20814 271518433 501(C)3 50000 N/A N/A MASSACHUSETTS INSTITUTE OF TECHNOLOGY 25 AMES ST CAMBRIDGE MA 02467 042103594 501(C)3 411044 N/A N/A GEORGIA REGENTS RESEARCH INSTITUTE 1120 15TH STREET AUGUSTA GA 30912 452019860 501(C)3 51592 N/A N/A CALIFORNIA INST FOR BIOMEDICAL RESEARCH 11119 NTORRY PINES RD LAJOLLA CA 92037 956047739 501(C)3 1742425 N/A N/A EMORY UNIVERSITY 69 JESSE HILL JR DRIVE ATLANTA GA 30322 580566256 501(C)3 449996 N/A N/A RETINA VITREOUS ASSOCIATES 610 SIERRA ROSE DR RENO NV 89144 953699305 106204 N/A N/A GEORGIA HEALTH SCIENCES UNIVERSITY 1120 15th Street ATLANTA GA 30394 586002053 501(C)3 107472 N/A N/A GEORGIA TECH RESEARCH CORP 505 TENTH STREET ATLANTA GA 30332 580603146 501(C)3 399997 N/A N/A MEDTRONIC 18000 DEVONSHIRE ST NORTHRIDGE CA 91325 411306950 4544000 N/A N/A STANFORD UNIVERSITY 300 PASTEUR DR PALA ALTO CA 94305 941156365 501(C)3 1549280 N/A N/A ELMAN RETINA GROUP 9114 PHILADELPHIA ROAD BALTIMORE MD 21237 521803322 30764 N/A N/A CENTER FOR RETINA MACULA DISEASE 250 AVE K WINTER HAVEN FL 33880 593028408 122995 N/A N/A NATIONAL JEWISH HEALTH 601 EAST 18TH STREET DENVER CO 80206 742044647 501(C)3 150000 N/A N/A OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PORTLAND OR 97239 237083114 501(C)3 299840 N/A N/A THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES RD LAJOLLA CA 92037 952160097 501(C)3 150000 N/A N/A THE SCHEPENS EYE RESEARCH INSTITUTE INC 20 STANIFORD ST BOSTON MA 02114 042129889 501(C)3 75000 N/A N/A THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(C)3 55384 N/A N/A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 415 CURIE BLVD PHILADELPHIA PA 19104 231352685 501(C)3 484723 N/A N/A THE BECKMAN RESEARCH INST OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)3 12302 N/A N/A LEXICON 8800 TECH FOREST PL THE WOODLANDS TX 77381 316025986 501(C)3 150000 N/A N/A UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER 920 MADISON AVE MEMPHIS TN 38163 626001636 501(C)3 64507 N/A N/A UNIV OF TEXAS HEALTH SCI CENTER 7703 FLOYDE CURL DR SAN ANTONIO TX 78229 741761309 501(C)3 49840 N/A N/A UNIVERSITY OF TEXAS SW MEDICAL CENTER AT DALLAS 800 WEST CAMPHELL ROAD DALLAS TX 75390 756002868 501(C)3 248627 N/A N/A UNIV OF COLORADO AT DENVER HEALTH SCI CENTER PO BOX 6511 DENVER CO 80045 846049811 501(C)3 1354612 N/A N/A UNIVERSITY OF FLORIDA 1600 SW ARCHER ROAD GAINESVILLE FL 32610 590974739 501(C)3 4055562 N/A N/A UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC 555 SOUTH FLOYD STREET LOUISVILLE KY 40202 611014882 501(C)3 164201 N/A N/A UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVE NORTH WORCESTER MA 01605 043167352 501(C)3 150000 N/A N/A UNIVERSITY OF MIAMI SCHOOL OF MEDICINE 1450 NW 10TH AVE MIAMI FL 33136 590624458 501(C)3 2069997 N/A N/A UNIVERSITY OF VIRGINIA 104 MIDMONT LN CHARLOTTESVILLE VA 22902 416042488 501(C)3 428761 N/A N/A UNIVERSITY OF MICHIGAN 1331 EAST ANN STREET ANN ARBOR MI 48109 386006309 501(C)3 1693269 N/A N/A MASSACHUSETTS EYE & EAR INFIRMARY 243 CHARLES STREET BOSTON MA 02114 042103591 501(C)3 5614 N/A N/A UNIVERSITY OF PITTSBURGH E 1140 STARZL PITTSBURGH PA 15261 113708851 501(C)3 535071 N/A N/A UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO 3333 CA ST SAN FRANCISCO CA 94122 956006143 501(C)3 5721724 N/A N/A UNIVERSITY OF SOUTH FLORIDA 3650 SPECTRUM BLVD TAMPA FL 33612 593102112 501(C)3 106856 N/A N/A NGM BIOPHARMACEUTICALS 630 GATEWAY BLVD SOUTH SAN FRANCISCO CA 94080 261679911 609624 N/A N/A UNIVERSITY OF WISCONSIN-MADISON 21 NORTH PARK MADISON WI 53706 396006492 501(C)3 198234 N/A N/A UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)3 196864 N/A N/A VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 620476822 501(C)3 920225 N/A N/A WASHINGTON UNIVERSITY IN ST LOUIS 4559 SCOTT AVE ST LOUIS MO 63110 430653611 501(C)3 860000 N/A N/A NEW YORK EYE & EAR INFIRMARY 310 EAST 14TH STREET NEW YORK NY 10003 135562304 17541 N/A N/A YALE UNIVERSITY 149 ELM STREET NEW HAVEN CT 06520 060646973 501(C)3 2907667 N/A N/A RETINA CENTERPC 1775 W SAINT MARYS Rd TUSCON AZ 85704 860796075 15291 N/A N/A THE BROAD INSTITUTE OF HARVARD & MIT 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)3 618958 N/A N/A DUKE UNIVERSITY 4321 MEDICAL PARK DR DURHAM NC 27704 560532129 501(C)3 408883 N/A N/A RETINA CONSULTANTS HOUSTON 6560 FANNIN ST HOUSTON TX 77030 742109903 7604 N/A N/A XERIS PHARMACEUTICALS 3208 RED RIVER STREET AUSTIN TX 78759 120335242 247202 N/A N/A FLORIDA RETINA INST 1025 PRIMERA LAKE MARY FL 32746 592009089 56581 N/A N/A RUTGERS THE STATE UNIVERSITY OF NJ 200 UNIVERSITY AVE NEWARK NJ 07107 122600186 501(C)3 176540 N/A N/A JAEB CENTER FOR HEALTH RESEARCH FND 15310 Amberly Drive TAMPA FL 33647 593187624 501(C)3 1354148 N/A N/A VIACYTE 3550 GENERAL ATOMICS SAN DIEGO CA 92121 999999999 2000000 N/A N/A SOUTHERN METHODIST UNIVERSITY 6425 BOAZ LANE DALLAS TX 75275 560657294 501(C)3 110000 N/A N/A AMYLIN PHARMACEUTICALS 9360 Towne Centre Drive SAN DIEGO CA 92121 753019302 222833 N/A N/A UNIVERSITY OF ARIZONA 811 N Euclid Ave Tucson AZ 85724 113661893 501(C)3 454434 N/A N/A COLUMBIA UNIVERSITY PO BOX 29789 NEW YORK NY 10087 135598093 501(C)3 498543 N/A N/A NEW YORK UNIVERSITY MEDICAL SCHOOL 550 1ST AVE NEW YORK NY 10016 111630830 501(C)3 136628 N/A N/A RETINA GROUP OF FLORIDA 5601 N DIXIE HWY FORT LAUDERDALE FL 33334 650017482 11811 N/A N/A RETINA MACULA INSTITUTE 4201 TORRANCE TORRANCE CA 90503 200804641 105203 N/A N/A RETINA INSTITUTE OF HAWAII 1620 ALA MOANA BLVD HONOLULU HI 96815 990357157 25785 N/A N/A SOUTHEAST RETINA CENTER 3685 WHEELER ROAD AUGUSTA GA 30909 581594221 69721 N/A N/A TEXAS RETINA ASSOCIATES 9600 NORTH CENTRAL EXPRESSWAY DALLAS TX 75231 751362336 84603 N/A N/A UNIVERSITY OF ALABAMA COLLEGE DRIVE BIRMINGHAM AL 35294 636001138 501(C)3 926554 N/A N/A MASSACHUSETTS GENERAL HOSPITAL 55 FRIUT STREET BOSTON MA 02114 042697983 501(C)3 1698954 N/A N/A NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 231352685 501(C)3 1224461 N/A N/A WINTHROP INSTITUTE HOSPITAL 95 MINEOLA BLV MINEOLA NY 11501 111633486 501(C)3 115000 N/A N/A SPOKANE EYE CLINIC 427 S BERNARD ST SPOKANE WA 99204 452887234 51167 N/A N/A TANDEM DIABETES CARE INC 11065 ROSELLE SAN DIEGO CA 92121 204327508 1750000 N/A N/A UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501(C)3 309103 N/A N/A RETINA RESEARCH CENTER 3705 MEDICAL PARKWAY AUSTIN TX 78705 711023026 84816 N/A N/A RETINAL CONSULTANTS OF ARIZONA 1101 MISSOURI AVE PHOENIX AZ 85014 860708606 39331 N/A N/A STATE UNIVERSITY OF NY AT BUFFALO 12 CAPEN HALL BUFFALO NY 14260 141368361 501(C)3 240113 N/A N/A GENOMICS INSTITUTE-NOVARTIS RES FND 10675 JOHN HOPKINS DR SAN DIEGO CA 92121 223610512 3319779 N/A N/A ILLINOIS INSTITUTE OF TECHNOLOGY 3300 SOUTH FEDERAL STREET CHICAGO IL 60616 362170136 501(C)3 276961 N/A N/A SANFORD RESEARCH 2301 E 60TH ST NORTH SIOUX FALLS SD 57104 460450378 664999 N/A N/A T1D EXCHANGE 11 AVE DE LAFAYETTE BOSTON MA 02111 451623549 896152 N/A N/A UNIVERSITY OF MINNESOTA 80 SOUTH 8TH STREET MINNEAPOLIS MN 55455 416007513 501(C)3 764297 N/A N/A BD DIABETES CARE 6840 CAROTHERS PWY FRANKLIN LAKES NJ 07417 999999999 3087500 N/A N/A UNIVERSITY OF VERMONT 1000 UNIVERSITY WAY COLCHESTER VT 05446 030179440 501(C)3 165000 N/A N/A VITREO-RETINAL ASSOCIATES 3355 EAGLE PARK GRAND RAPIDS MI 49525 999999999 14172 N/A N/A WINIFRED MASTERSON BURK MED CENTER 785 Mamaroneck Avenue WHITE PLAINS NY 10605 133434924 109966 N/A N/A MOUNT SINAI SCHOOL OF MEDICINE 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 113617119 501(C)3 385384 N/A N/A THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 51608 N/A N/A MAYO CLINIC 201 W CENTER STREET ROCHESTER MN 55905 416011702 501(C)3 108942 N/A N/A MEDICAL CENTER OPHTHALMOLOGY 11900 CROWN POINT SAN ANTONIO TX 78240 742143569 12057 N/A N/A MEMORIAL SLOAN-KETTERING CANCER CENTER 641 LEXINGTON AVE NEW YORK NY 10017 131924236 110000 N/A N/A MICHIGAN EYE CARE 29877 TELEGRAPH ROAD SOUTHFIELD MI 48034 383160340 72741 N/A N/A MIDWEST EYE INSTITUTE 201 PENNSYLVANIA AVE INDIANAPOLIS IN 46280 383642669 25464 N/A N/A RUTGERS THE STATE UNIVERSITY 175 UNIVERSITY AVE NEWARK NJ 07107 462354111 501(C)3 176540 N/A N/A UNIVERSITY OF OKLAHOMA 660 PARRINGTON OVAL RD OKLAHOMA CITY OK 73126 736017987 501(C)3 303320 N/A N/A THERMALIN DIABETES 10000 CEDAR AVE CLEVELAND OH 44106 180057439 108382 N/A N/A UNIVERSITY OF HOUSTON 4888 LOOP CENTRAL DR HOUSTON TX 77204 746001399 501(C)3 249666 N/A N/A UNIVERSITY OF WASHINGTON 1401 15TH AVE SEATTLE WA 98195 911486484 501(C)3 51592 N/A N/A VALLEY RETINA INSTITUTE 1309 RIDGE ROAD MCALLEN TX 78503 742768498 29281 N/A N/A WESTERN MICHIGAN UNVERSITY 1903 W MICHIGAN ANE KALAMAZOO MI 49008 454135256 501(C)3 106121 N/A N/A UNIVERSITY OF ROCHESTER 500 JOESPH WILLSON BLVD ROCHESTER NY 14611 160743209 501(C)3 165000 N/A N/A 77 36 GRANT MONITORING PROCEDURES Research grants are awarded by the recommendations of a professional scientific staff at JDRF based on input from outside scientific reviewers and patient advocates. The following areas are evaluated: (1) The scientific merit of the application. (2) The relationship of the research to the causes, prevention and cure of diabetes and its complications. Also considered are the merits of the institutions and/or sponsors of the applicant, and the applicant's commitment to the continuing diabetes research programs. JDRF staff reviews expenditures reported by an institution. X X true true X X X X X false false false false false false false true false DR RICHARD A INSEL EVP RESEARCH 486450 0 0 0 50000 0 0 0 0 0 536450 0 0 0 EDWARD J SEBALD CFO & ASST. TRES 232834 0 0 0 0 0 0 0 0 0 232834 0 0 0 JEFFREY BREWER PRESIDENT AND CEO 262500 0 0 0 0 0 0 0 0 0 262500 0 0 0 GERRI BOSTICK 248741 0 13135 0 0 0 0 0 0 0 261876 0 0 0 JAMES SZMAK 337667 0 20431 0 117500 0 0 0 0 0 475598 0 0 0 JULIA GREENSTEIN CHAIR, DEVELOPMENT 254203 0 10539 0 0 0 0 0 0 0 264742 0 0 0 DAVID WHEADON CHAIR, INVESTMENTS 295097 0 0 0 115428 0 0 0 0 0 410525 0 0 0 AARON KOWALSKI 234712 0 9984 0 0 0 0 0 0 0 244696 0 0 0 MARGO LUCERO BOARD MEMBER 231909 0 11561 0 0 0 0 0 0 0 243470 0 0 0 CYNTHIA RICE BOARD MEMBER 230552 0 9080 0 0 0 0 0 0 0 239632 0 0 0 DAVID WHEADON EVP, RESEARCH & ADVOCACY 295097 115428 9262 419787 AARON KOWALSKI VP, RESEARCH 234712 9984 13367 22373 280436 MARGO LUCERO VP, CORPORATE DEVELOPMENT 231909 11561 23422 266892 CYNTHIA RICE SVP, GOV'T RELATIONS/ ADVOCACY 230552 9080 12689 22534 274855 HOUSING ALLOWANCE SCHEDULE J PART I, LINE 1A Dr. Insel, highest compensated employee, received a housing allowance that was grossed up as per the terms of his employment agreement. For the 2013 calendar year, the housing allowance provided to Dr. Insel was $50,000; such amount was treated as taxable compensation and included in his Form W-2. This amount was also reported on Schedule J, Part II, Col. (B)(iii). OTHER REPORTABLE COMPENSATION- SCHEDULE J PART II, COL (B)(iii) DAVID WHEADON, RECEIVED RELOCATION EXPENSES FOR THE 2013 CALENDAR YEAR, THE ALLOWANCE PROVIDED TO DAVID WHEADON WAS $115,428; SUCH AMOUNT WAS TREATED AS TAXABLE COMPENSATION AND INCLUDED IN HIS FORM W-2. THIS AMOUNT WAS ALSO REPORTED ON SCHEDULE J, PART II, COL (B)(iii). JAMES SZMAK, RECEIVED RELOCATION EXPENSES FOR THE 2013 CALENDAR YEAR, THE ALLOWANCE PROVIDED TO JAMES SZMAK WAS $117,500; SUCH AMOUNT WAS TREATED AS TAXABLE COMPENSATION AND INCLUDED IN HIS FORM W-2. THIS AMOUNT WAS ALSO REPORTED ON SCHEDULE J, PART II, COL (B)(iii). NON-FIXED PAYMENTS FORM 990, SCHEDULE J, PART I, LINE 7 JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL. (B) (II). RUTH HENDREN DAUGHTER OF MIKE HENDREN 51086 EMPLOYMENT AT JDRF INT. false ELIZABETH KECKLER DAUGHTER OF ELLEN LEAKE 76938 EMPLOYMENT AT JDRF INT. false DDC ADVOCACY JOHN BRADY, PRIN & DIR. 656000 SEE PART V false TANDEM DIABETES CARE DICK ALLEN, DIRECTOR 1750000 SEE PART V false BUSINESS TRANSACTIONS SCHEDULE L, PART IV, COLUMN C FOR THE TWO EMPLOYEES LISTED IN PART IV, COLUMN C, TOTAL COMPENSATION INCLUDES EMPLOYER PAID BENEFITS. FOR JDRF BOARD MEMBER JOHN BRADY WHO IS LISTED IN PART IV, LINE 3, THE SUM IN COLUMN (C) WAS THE AMOUNT PAID BY JDRF TO DDC FOR ADVOCACY CONSULTING; MR. BRADY IS A PRINCIPAL OWNER & MEMBER OF THE DDC ADVOCACY BOARD OF DIRECTORS. JDRF CHAIRMAN OF THE BOARD, DICK ALLEN, WHO IS LISTED IN PART IV, LINE 4, WAS ON THE BOARD OF TANDEM DIABETES CARE, INC WHO JDRF FUNDED GRANTS IN FY13 & FY14 FOR $650,000 AND $1,750,000 RESPECTIVELY. X 1 50000 TICKET SALES X 270 3524596 NET PROCEEDS OF SALE X MISC AUCTION ITEMS DONATED 10000 11111092 THRIFT SHOP 1 false true true THIRD PARTY ASSISTANCE LINE 32B THE CAR PROGRAM LLC IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND THEY ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, THE CAR PROGRAM LLC HANDLES ALL IRS 1098-C REPORTING. THE CAR PROGRAM LLC IS A LICENSED PROFESSIONAL FUNDRAISER AND IS LICENSED IN THE STATES THAT REQUIRE IT TO REGISTER. FOR THE PERIOD ENDING 6/30/14, THE CAR PROGRAM LLC RAISED $309,522 WITH TOTAL EXPENSES OF $146,037. A NET CHECK IS PAID DIRECTLY TO JDRF. JDRF DOES NOT PAY THE CAR PROGRAM ANY EXPENSES OR FEES DIRECTLY. TOTAL NET REVENUE FOR FY-14 WAS $163,485. NONCASH CONTRIBITIONS FORM 990, SCHEDULE M, PAGE 1, TYPES OF PROPERTY THE AMOUNTS LISTED IN PART I LINES 6 & 9 ARE THE ACTUAL AMOUNT THAT DONORS HAVE DONATED FOR VEHICLES AND SECURITIES. LINE 25 COLUMN(b),IS AN ESTIMATE OF MISC ITEMS THAT ARE SOLD AT VARIOUS AUCTIONS & RAFFLES. ORGANIZATION'S MISSION FORM 990, PART III, LINE 1 JDRF IS THE LEADING GLOBAL ORGANIZATION FOCUSED ON TYPE 1 DIABETES (T1D) RESEARCH. JDRF'S GOAL IS TO PROGRESSIVELY REMOVE THE IMPACT OF T1D FROM PEOPLE'S LIVES UNTIL WE ACHIEVE OUR VISION OF A WORLD WITHOUT T1D. JDRF COLLABORATES WITH A WIDE SPECTRUM OF PARTNERS AND IS THE ONLY ORGANIZATION WITH THE SCIENTIFIC RESOURCES, REGULATORY INFLUENCE AND A WORKING PLAN TO BRING LIFE-CHANGING THERAPIES FROM THE LAB TO THE T1D COMMUNITY. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($98,317,342)JDRF IS THE ONLY GLOBAL ORGANIZATION WITH A STRATEGIC RESEARCH PLAN TO END T1D. OUR PLAN ENSURES THAT THERE WILL BE AN ONGOING STREAM OF LIFE-CHANGING THERAPIES MOVING THROUGH THE RESEARCH PIPELINE FROM DEVELOPMENT TO THE MARKETPLACE THAT LESSEN THE IMPACT OF T1D UNTIL WE ELIMINATE THE DISEASE FROM PEOPLE'S LIVES COMPLETELY AND CREATE A WORLD WITHOUT T1D. JDRF RESEARCH PROGRAMS ARE FOCUSED ON DRIVING THE RESEARCH PIPELINE TO EXPEDITE AND SUSTAIN MEANINGFUL SCIENTIFIC PROGRESS WHICH IS KEY TO DELIVERING PROGRESSIVELY ADVANCED T1D THERAPIES. TO ACCOMPLISH THIS, JDRF IS: 1) DRIVING RESEARCH ACROSS THE ENTIRE SCIENTIFIC AND DEVELOPMENT SPECTRUM, FROM DISCOVERY IN THE LABORATORY TO CLINICAL STUDIES TO DELIVERY TO PATIENT; 2) COLLABORATING WITH PUBLIC, PRIVATE, ACADEMIC, AND CORPORATE PARTNERS TO EXPEDITE DELIVERY OF REAL-WORLD SOLUTIONS; AND 3) ADVOCATING WITH GOVERNMENTS, REGULATORS, AND HEALTH INSURERS FOR PROGRESS THAT WILL IMPROVE LIVES TODAY AND LEAD TO A CURE TOMORROW. JDRF RESEARCH IS FOCUSED ON THE FOLLOWING SEVEN KEY THERAPY AREAS. ARTIFICIAL PANCREAS - SYSTEMS THAT CAN DELIVER MORE EFFECTIVE AND PRECISE INSULIN AND MULTI-HORMONE THERAPY. COMPLICATIONS - THERAPIES THAT PREVENT OR BETTER TREAT T1D-RELATED DAMAGE SUCH AS EYE AND KIDNEY DISEASE. ENCAPSULATION - REPLACEMENT CELL THERAPIES THAT CAN PROVIDE LONG-TERM RELIEF FROM INSULIN THERAPY. GLUCOSE CONTROL - TREATMENTS THAT WILL IMPROVE THE BODY'S GLYCEMIC AND METABOLIC BALANCE THROUGH INNOVATIVE AND PERSONALIZED THERAPIES ABOVE AND BEYOND THE USE OF INSULIN ALONE. SMART INSULIN - NOVEL INSULINS THAT CAN TURN ON AND OFF IN RESPONSE TO CHANGING BLOOD-GLUCOSE LEVELS. RESTORATION - RESTORING THE BODY'S ABILITY TO PRODUCE INSULIN, WHICH WOULD PROVIDE A BIOLOGICAL CURE FOR T1D. PREVENTION - THERAPIES THAT WILL KEEP INDIVIDUALS, ESPECIALLY THOSE AT HIGHER RISK, FROM EVER DEVELOPING T1D. LINE 4B ($21,415,048) TO HELP DEFINE AND DIRECT ITS RESEARCH PROGRAMS AND TO FOSTER COLLABORATION WITH OTHERS INVOLVED WITH T1D RESEARCH, JDRF ORGANIZES SCIENTIFIC MEETINGS, SYMPOSIA, WORKSHOPS, AND CONFERENCES. DEPENDING ON THEIR SPECIFIC GOAL, THESE EVENTS MAY INCLUDE SCIENTIFIC EXPERTS FROM ACADEMIA, GOVERNMENTS, AND INDUSTRY, REGULATORS, JDRF VOLUNTEERS, AND/OR REPRESENTATIVE PEOPLE WITH T1D OR THOSE WHO HAVE A FAMILY MEMBER WITH T1D. THIS WORK PROVIDES OPPORTUNITIES TO REVIEW RESEARCH PROPOSALS AND ENSURE JDRF'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND FOR JDRF TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH IT IS FUNDING AND MANAGING. THESE EVENTS ALSO ENHANCE JDRF'S ABILITY AND OPPORTUNITY TO FORECAST FUTURE SCIENTIFIC DIRECTIONS, JUDGE THE POTENTIAL EFFICIENCY AND EFFECTIVENESS OF NEW RESEARCH PATHWAYS, INFLUENCE THE DIRECTION OF NON-JDRF RESEARCH PROGRAMS, AND IDENTIFY GAPS WHERE JDRF CAN FOCUS ITS FUNDING TO MAKE THE MOST IMPACT. THESE EVENTS STRENGTHEN JDRF'S LEADERSHIP ROLE IN T1D RESEARCH AND ENABLES IT TO DRIVE THE MOST EFFECTIVE STRATEGIC FUNDING PLAN TO BRING ABOUT A CONTINUOUS FLOW OF LIFE-CHANGING THERAPIES AND, ULTIMATELY, A CURE FOR T1D. THESE ARE ALSO KEY TO HELPING ALIGN GLOBAL EFFORTS TOWARDS A COMMON GOAL OF CREATING A WORLD WITHOUT T1D. LINE 4C ($51,463,000) BECAUSE OF ITS LEADING ROLE IN T1D RESEARCH GLOBALLY, JDRF IS IN A UNIQUE POSITION TO PROVIDE PUBLIC EDUCATION ABOUT DIABETES, ESPECIALLY T1D, AND ITS COMPLICATIONS. JDRF IS A RECOGNIZED, AUTHORITATIVE SOURCE OF INFORMATION ABOUT T1D AND T1D-RELATED RESEARCH AND RESEARCH PROGRESS. JDRF'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE WITH THE DISEASE AND THEIR FAMILIES, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE, AND THE GENERAL PUBLIC. JDRF EDUCATES PEOPLE ABOUT THE WARNING SIGNS OF T1D, WHICH CAN BE PROFOUNDLY HELPFUL IN ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL, SHORT-TERM, LIFE-THREATENING CONSEQUENCES OF THE DISEASE. JDRF ALSO PROVIDES KEY INFORMATION ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS, AND ABOUT HUMAN CLINICAL TRIALS IN WHICH PEOPLE WITH THE DISEASE CAN PARTICIPATE TO HELP TEST POTENTIAL NEW THERAPIES. JDRF STAFF IN THE NATIONAL OFFICE, IN LOCAL CHAPTER OFFICES ACROSS THE UNITED STATES AND IN AFFILIATE OFFICES AROUND THE GLOBE ROUTINELY ORGANIZE AND SUPPORT PROGRAMS DESIGNED TO HELP PEOPLE IDENTIFY AND DIAGNOSE T1D EARLIER AND TO HELP PEOPLE WITH T1D STAY HEALTHIER SO THAT THEY CAN BENEFIT FROM A CURE AND TREATMENTS AS THEY ARE DEVELOPED. 990 REVIEW PROCESS FORM 990 SECTION B, PART VI, QUESTION 11B THE FIRST STEP IN THE FORM 990 REVIEW PROCESS BEGINS AT THE FINANCE LEVEL WITH THE ORGANIZATION'S TAX MANAGER WORKING WITH OUTSIDE TAX ADVISORS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE RETURN IS PREPARED AND CHECKED FOR ACCURACY. AFTER A DRAFT RETURN IS PREPARED, THE SECOND STEP IN THE REVIEW PROCESS INCLUDES A REVIEW OF THE DRAFT RETURN BY OUR TAX ADVISOR, ATTORNEY, DIRECTOR OF FINANCE AND CHIEF FINANCIAL OFFICER PRIOR TO AN AUDIT COMMITTEE REVIEW. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT FORM 990 ARE ADDRESSED AND MADE. THE THIRD STEP IN THE REVIEW PROCESS IS FOR THE JDRF AUDIT COMMITTEE TO REVIEW THE RETURN WITH OUR OUTSIDE TAX ADVISORS. ONCE THE RETURN IS APPROVED WITH ALL CHANGES AND READY TO FILE, IT IS PASSED ON TO THE BOARD. THE FOURTH AND FINAL STEP IN THE REVIEW PROCESS IS TO PROVIDE A FINAL COPY OF THE RETURN TO EACH VOTING MEMBER OF THE JDRF BOARD OF DIRECTORS BEFORE E-FILING THE FORM 990 WITH THE INTERNAL REVENUE SERVICE. CONFLICT OF INTEREST POLICY FORM 990- PART VI-SECT B, LINE 12C ALL OFFICERS, DIRECTORS, KEY EMPLOYEES, BOARD AND COMMITTEE MEMBERS (BOTH CHAPTERS AND INTERNATIONAL BOARDS) ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY ANNUALLY AND DISCLOSE ANY CONFLICTS. THE OFFICE OF THE PRESIDENT HANDLES THIS PROCESS AND JDRF'S INTERNAL AUDIT DEPARTMENT ANNUALLY AUDITS TO ENSURE COMPLIANCE. IF ANY CONFLICT DOES ARISE, THE BOARD MEMBERS WITH THE CONFLICTS WILL RECUSE THEMSELVES FROM THE MEETING AND/OR VOTE. PUBLIC DOCUMENTS FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS MAIN WEBSITE: www.jdrf.org. THE PUBLIC MAY ACCESS COPIES OF JDRF'S W-9, ANNUAL REPORT, 990 TAX RETURNS, 501(C)(3) IRS LETTER, & AUDITED FINANCIALS, AT THE FOLLOWING LINK: http://jdrf.org/about-jdrf/financials/ EXECUTIVE COMPENSATION POLICY PART VI, SECTION B, LINES 15a & 15b USING RELIABLE DATA, THE ORGANIZATION OBTAINS OBJECTIVE DATA ON COMPARABLE SALARIES AND BENEFITS FOR SIMILAR ORGANIZATIONS WITH LIKE KIND POSITIONS. THE COMPENSATION AND BENEFITS ARE REVIEWED BY AN AUTHORIZED BODY OR COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, WHO DETERMINE THAT THE COMPENSATION OF EXECUTIVES AND KEY PERSONNEL IS REASONABLE AND WITHIN ACCEPTABLE LIMITS. THE AUTHORIZED BODY OR COMMITTEE ADEQUATELY DOCUMENTS THE REVIEW OF JDRF EXECUTIVE COMPENSATION AND BENEFITS AND THE BASIS FOR ITS DETERMINATION, CONTEMPORANEOUSLY IN THE MINUTES OF THE COMPENSATION COMMITTEE. DURING THE TAX YEAR ENDED JUNE 30, 2014, JDRF'S COMPENSATION COMMITTEE MET ON DECEMBER 6, 2013 TO REVIEW SALARIES AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE. CHANGE IN OFFICERS DEREK RAPP BECAME PRESIDENT & CEO REPLACING JEFFREY BREWER IN JULY 2014. HE DID NOT HAVE REPORTABLE INCOME FOR THE YEAR ENDING 6/30/2014. MARK GREENE BECAME CHIEF FINANCIAL OFFICER REPLACING EDWARD SEBALD IN JULY 2014. HE DID NOT HAVE REPORTABLE INCOME FOR THE PERIOD ENDING 6/30/14. DIABETES INVESTMENT FUND LLC C/O JDRF - 26 BROADWAY 14TH FLOOR NEW YORK NY 10004 274967989 INVESTMENT DE JDRF CHARITABLE REMAINDER TRUST (5) ANNUITY PA false false false false false false false false false false false false false false false false false false false